Measles Rubella Cipla NLT 1000,0 CCID50 Powder and solvent for solution for subcutaneous injection
PDF Leaflet Revision Date: 12 May 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Active immunisation against measles and rubella.
Dosage (summary)
Single dose of 0.5 mL for all ages.
Special Populations
- Immunocompromised patients
- Adolescent and adult females of childbearing age
Pregnancy & Breastfeeding
Contraindicated in pregnancy; no data on breastfeeding.
Key Drug Interactions
- Immunosuppressants
- Immunoglobulins
- Blood products
Contraindications
- Previous anaphylactic reaction
- Severe immunosuppression
- Pregnancy
- Allergy to neomycin or cow's milk
Common side effects
- Injection site pain
- Fever
- Rash
- Arthralgia
Counselling Points
- Inform about potential mild side effects
- Advise to report any severe reactions
- Ensure proper storage and handling of vaccine
Serious warnings
- Observe for 30 mins post-vaccination for allergic reactions
- Do not inject intravascularly
Important Disclaimer
The Measles Rubella Cipla NLT 1000,0 CCID50 Powder and solvent for solution for subcutaneous injection professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
